scholarly journals A new frontier for amyloid PET imaging: multiple sclerosis

2018 ◽  
Vol 46 (2) ◽  
pp. 276-279 ◽  
Author(s):  
Silvia Morbelli ◽  
Matteo Bauckneht ◽  
Selene Capitanio ◽  
Matteo Pardini ◽  
Luca Roccatagliata ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Pet Imaging ◽  
Amyloid Pet ◽  
New Frontier ◽  
Amyloid Pet Imaging

scholarly journals Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging

2016 ◽  
Vol 7 ◽  
Author(s):  
Jordi A. Matías-Guiu ◽  
Celia Oreja-Guevara ◽  
María Nieves Cabrera-Martín ◽  
Teresa Moreno-Ramos ◽  
José Luis Carreras ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Pet Imaging ◽  
Amyloid Pet ◽  
Amyloid Proteins ◽  
Amyloid Pet Imaging

scholarly journals Amyloid PET imaging in multiple sclerosis: an 18F-florbetaben study

BMC Neurology ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Jordi A. Matías-Guiu ◽  
María Nieves Cabrera-Martín ◽  
Jorge Matías-Guiu ◽  
Celia Oreja-Guevara ◽  
Cristina Riola-Parada ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Pet Imaging ◽  
Amyloid Pet ◽  
Amyloid Pet Imaging

scholarly journals Using amyloid PET imaging to diagnose Alzheimer’s disease in patients with multiple sclerosis

2020 ◽  
Vol 267 (11) ◽  
pp. 3268-3273 ◽  
Author(s):  
Magdalena Kolanko ◽  
Zarni Win ◽  
Neva Patel ◽  
Omar Malik ◽  
Christopher Carswell ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Pet Imaging ◽  
Case Series ◽  
Amyloid Pet ◽  
Neuropsychological Profile ◽  
Therapeutic Decisions ◽  
Amyloid Pet Imaging

Abstract Background Cognitive dysfunction affects 40–60% of individuals with multiple sclerosis (MS). The neuropsychological profile commonly consists of a subcortical pattern of deficits, although a proportion of patients have a severe progressive cortical dementia. However, patients with MS can be affected by other neurodegenerative diseases, such as Alzheimer’s disease (AD). Little is known about the co-existence of these two conditions but distinguishing dementia due to MS alone from a coexisting neurodegenerative disease is challenging. Amyloid PET imaging has allowed improved AD diagnosis, especially in patients with atypical presentations or multiple possible causes of cognitive impairment. Amyloid PET demonstrates increased cortical signal in AD, whereas reductions in subcortical uptake are associated with demyelination. To the authors knowledge, there are no reports of clinical Amyloid PET use in MS patients with dementia. Methods Here, three MS patients presenting to the Cognitive Neurology Clinic with progressive cognitive impairment are described. Due to lack of diagnostic clarity from standard investigations, they underwent Amyloid PET Imaging with 18F-florbetapir according to established appropriate use criteria and after review by a multidisciplinary team. Results Two patients were diagnosed with AD based on positive Amyloid PET imaging and were subsequently started on cholinesterase inhibitor treatment. The other patient had a negative scan, leading to further investigations and identification of another potential cause of worsening cognitive impairment. Conclusions The experience from this case series suggests that Amyloid PET Imaging may be of diagnostic value in selected patients with MS and dementia. In these individuals, it may provide diagnostic clarity and assist with therapeutic decisions.

P2-325: AMYLOID PET IMAGING IN A COMMUNITY NEUROLOGY PRACTICE: FEASIBILITY AND CLINICAL OUTCOMES

2006 ◽  
Vol 14 (7S_Part_15) ◽  
pp. P807-P807
Author(s):  
Michael H. Rosenbloom ◽  
Kathryn A. Wyman-Chick ◽  
Lauren O. Erickson ◽  
Paul Carolan ◽  
Joshua Johnson ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Pet Imaging ◽  
Amyloid Pet ◽  
Amyloid Pet Imaging

scholarly journals Amyloid PET imaging: a challenge for research in clinical neuroimaging

2015 ◽  
Vol 3 (1) ◽  
pp. 3-5
Author(s):  
Kirk Frey ◽  
Daniela Perani
Keyword(s):  
Pet Imaging ◽  
Amyloid Pet ◽  
Amyloid Pet Imaging

scholarly journals Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging

2018 ◽  
Vol 32 (1) ◽  
pp. 35-42 ◽  
Author(s):  
Rafid Mustafa ◽  
Jared R. Brosch ◽  
Gil D. Rabinovici ◽  
Bradford C. Dickerson ◽  
Maria C. Carrillo ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Amyloid Pet ◽  
Clinical Use ◽  
Amyloid Pet Imaging

scholarly journals A Review of Diagnostic Impact of Amyloid Positron Emission Tomography Imaging in Clinical Practice

2018 ◽  
Vol 46 (3-4) ◽  
pp. 154-167 ◽  
Author(s):  
Yejin Kim ◽  
Paul Rosenberg ◽  
Esther Oh
Keyword(s):  
Positron Emission Tomography ◽  
Clinical Practice ◽  
Pet Imaging ◽  
Clinical Utility ◽  
Patient Management ◽  
Emission Tomography ◽  
Amyloid Pet ◽  
Diagnostic Confidence ◽  
Positron Emission ◽  
Amyloid Pet Imaging

Background: Molecular imaging of brain amyloid for the diagnosis of Alzheimer’s disease (AD) using positron emission tomography (PET) has been approved for use in clinical practice by the Food and Drug Administration (FDA) since 2012. However, the clinical utility and diagnostic impact of amyloid PET imaging remain controversial. We conducted a review of the recent studies investigating clinical utility of amyloid PET imaging with focus on changes in diagnosis, diagnostic confidence, and patient management. Summary: A total of 16 studies were included in the final analysis. Overall rate of changes in diagnosis after amyloid PET ranged from 9 to 68% (pooled estimate of 31%, 95% CI 23–39%). All studies reported overall increase in diagnostic confidence or diagnostic certainty after amyloid PET. Changes in patient management ranged from 37 to 87%; the most common type of change in management reported was either the initiation or discontinuation of planned AD medications. Key Messages: Amyloid PET imaging led to moderate to significant changes in diagnosis, diagnostic confidence, and subsequent patient management. It may be most useful in patients with high level of diagnostic uncertainty even after the completing the standard workup.

Sign in / Sign up

Export Citation Format

Share Document